Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Published
Published
Guidance, NICE advice and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 active)
Skip to results
Filter by title or keyword
Filter
Last updated date
Last updated date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (3)
Type
Type
Guidance (756)
Guidance programme
(
1 selected
)
Guidance programme
Antimicrobial prescribing guidelines (20)
Cancer service guidelines (8)
Clinical guidelines (223)
COVID-19 rapid guidelines (3)
Diagnostics guidance (47)
Health technology evaluations (18)
Highly specialised technologies guidance (27)
Interventional procedures guidance (598)
Medical technologies guidance (67)
Medicines practice guidelines (5)
NICE guidelines (339)
Public health guidelines (61)
Safe staffing guidelines (2)
Social care guidelines (71)
Technology appraisal guidance (756)
Apply filters
Showing 26 to 50 of 756
Sort by
Date
Title
Apply sorting
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Published guidance, NICE advice and quality standards
Title
Reference number
Published
Last updated
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments
TA947
31 January 2024
31 January 2024
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments
TA948
31 January 2024
31 January 2024
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal)
TA945
30 January 2024
30 January 2024
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer
TA946
17 January 2024
17 January 2024
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer
TA944
10 January 2024
10 January 2024
Targeted-release budesonide for treating primary IgA nephropathy
TA937
20 December 2023
20 December 2023
Ravulizumab for treating generalised myasthenia gravis (terminated appraisal)
TA940
20 December 2023
20 December 2023
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)
TA941
20 December 2023
20 December 2023
Empagliflozin for treating chronic kidney disease
TA942
20 December 2023
20 December 2023
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes
TA943
19 December 2023
19 December 2023
Risdiplam for treating spinal muscular atrophy
TA755
16 December 2021
15 December 2023
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
TA939
13 December 2023
13 December 2023
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)
TA938
7 December 2023
7 December 2023
Secukinumab for treating moderate to severe hidradenitis suppurativa
TA935
6 December 2023
6 December 2023
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)
TA936
30 November 2023
30 November 2023
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)
TA933
29 November 2023
29 November 2023
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms
TA934
29 November 2023
29 November 2023
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)
TA932
23 November 2023
23 November 2023
Zanubrutinib for treating chronic lymphocytic leukaemia
TA931
22 November 2023
22 November 2023
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments
TA930
15 November 2023
15 November 2023
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction
TA929
1 November 2023
1 November 2023
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine
TA928
1 November 2023
1 November 2023
Ranibizumab for treating diabetic macular oedema
TA274
27 February 2013
26 October 2023
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable
TA917
25 October 2023
25 October 2023
Tirzepatide for treating type 2 diabetes
TA924
25 October 2023
25 October 2023
Previous page
1
Current page
2
3
4
…
31
Page
2
of
31
Next page
Results per page
10
25
50
All
Back to top